OJEMDA net product revenues were approximately $29.0 million for the fourth quarter, bringing 2024 full-year revenue to approximately $57.2 million. The Company’s cash, cash equivalents and short-term investments totaled approximately $531.7 million as of December 31, 2024, as compared to $366.3 million on December 31, 2023. “We started 2025 with tremendous momentum based on our 2024 achievements and are well positioned to further our mission,” said Jeremy Bender, Ph.D., CEO. “Our priorities this year are to drive OJEMDA revenue, to continue investing in programs that leverage our expertise in development and commercialization, and to maintain a strong and durable financial position that allows us to operate independently from capital markets.” 2025 Upcoming Priorities and Milestones Continue to grow OJEMDA revenue in relapsed or refractory pLGG. Advance the existing pipeline, including the FIREFLY-2 Phase 3 clinical trial with tovorafenib in the front-line setting, and DAY301 in the Phase 1a/b trial. Pursue business development opportunities to expand the pipeline. Maintain a self-sustaining financial position for investing in durable growth.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DAWN:
- Day One Biopharmaceuticals preliminary FY24 OJEMDA product revenue $57.2M
- Day One Biopharmaceuticals price target lowered to $25 from $28 at BofA
- Day One Biopharmaceuticals (DAWN) Posts Stellar Q3 but with Extreme Concentration Risk
- Day One price target lowered to $34 from $39 at JonesResearch
- Day One Biopharmaceuticals Announces Leadership Transition
Questions or Comments about the article? Write to editor@tipranks.com